Novartis AG / Excellergy, Inc.

IgE-mediated Allergic Diseases (food allergy, chronic urticaria, allergic asthma)

26M US cases/yr · $4.5B Global anti-IgE therapeutic market (Xolair + adjacent, 2025)

Disease Overview

IgE-mediated allergic diseases are a family of chronic conditions driven by allergen-specific IgE antibodies binding to the high-affinity FcepsilonRI receptor on mast cells and basophils, triggering degranulation and release of histamine, leukotrienes, and cytokines. Food allergy affects approximately 1 in 10 US adults (~26 million) and 1 in 12-13 US children (~5.6 million), with peanut, tree nut, shellfish, milk, and egg as leading allergens; epidemiology data per AAFA and NIAID-funded household surveys. Chronic spontaneous urticaria (CSU) has a US annual prevalence of approximately 0.5-2.3%, translating to roughly 1.5-4.5 million affected adults. Allergic asthma affects approximately 60% of the ~25 million US asthma patients per CDC. These conditions share the IgE-FcepsilonRI axis as a therapeutic target. Anti-IgE biologics, most notably omalizumab (Xolair, approved 2003 for allergic asthma, 2014 for CSU, 2024 for food allergy), have demonstrated disease-modifying activity but do not remove receptor-bound IgE or fully downregulate FcepsilonRI expression. Next-generation anti-IgE antibodies such as Exl-111 aim to dissociate pre-bound IgE and drive deeper FcepsilonRI downregulation for faster, more complete symptom control across multiple IgE-driven indications.

Competitive Landscape

The anti-IgE therapy landscape is dominated by Xolair (omalizumab, Novartis/Genentech partnership), approved for allergic asthma (2003), CSU (2014), nasal polyposis (2020), and food allergy (2024), with combined global sales of approximately $4.3B in 2025. Novartis' prior next-generation anti-IgE candidate ligelizumab failed to demonstrate superiority over omalizumab in CSU Phase 3 trials and was discontinued. Competing biologics in overlapping IgE-driven indications include: dupilumab (Dupixent, Sanofi/Regeneron, IL-4Ralpha, approved in atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis, COPD); tezepelumab (Tezspire, AstraZeneca/Amgen, TSLP inhibitor, severe asthma); mepolizumab (Nucala, GSK, IL-5); benralizumab (Fasenra, AstraZeneca, IL-5R); reslizumab (Cinqair, Teva, IL-5); and in CSU specifically, BTK inhibitor remibrutinib (Novartis, Phase 3) and dupilumab (approved CSU 2025). Exl-111 enters with a differentiated mechanism: a half-life-extended high-affinity anti-IgE designed to dissociate receptor-bound IgE and drive FcepsilonRIalpha downregulation, potentially offering deeper and faster suppression than omalizumab with a broader label across food allergy, CSU/CIndU, and allergic asthma, including in pediatric populations.